Advanced Enzyme Technologies Ltd
ADVENZYMESAdvanced Enzyme Technologies Ltd
ADVENZYMES
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 30.30 | 3.03 | 1.37% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 30.03 | 3.41 | 1.36% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Advanced Enzyme Technologies is engaged in the research and development, manufacturing and marketing of over 400 products developed from over 60 indigenous enzymes.
Investor Presentation
View olderPeers
Compare with peersGujarat Fluorochemicals Ltd
Vinati Organics Ltd
Navin Fluorine International Ltd
Akzo Nobel India Ltd
Clean Science and Technology Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ cr.
All values in ₹ cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 295.05 | 331.57 | 392.41 | 424.63 | 449.63 | 510.69 | 535.80 | 566.10 | 660.53 | 659.87 | ||||||||||
Raw Materials | 69.66 | 70.14 | 80.33 | 65.95 | 90.83 | 100.21 | 130.32 | 127.53 | 155.47 | 431.79 | ||||||||||
| Power & Fuel Cost | 10.17 | 12.87 | 18.10 | 19.29 | 19.37 | 21.45 | 29.95 | 38.10 | 40.92 | |||||||||||
| Employee Cost | 44.50 | 50.70 | 68.60 | 80.23 | 80.19 | 87.11 | 103.96 | 114.80 | 128.37 | |||||||||||
| Selling & Administrative Expenses | 23.50 | 25.61 | 38.41 | 40.04 | 37.58 | 37.72 | 51.80 | 56.22 | 60.11 | |||||||||||
| Operating & Other expenses | 12.47 | 18.00 | 20.64 | 30.84 | 12.65 | 22.78 | 10.77 | 50.56 | 48.48 | |||||||||||
EBITDA | 134.75 | 154.25 | 166.33 | 188.28 | 209.01 | 241.42 | 209.00 | 178.89 | 227.18 | 228.08 | ||||||||||
| Depreciation/Amortization | 8.72 | 12.76 | 18.30 | 21.12 | 25.78 | 28.72 | 34.98 | 35.03 | 35.24 | 35.39 | ||||||||||
| PBIT | 126.03 | 141.49 | 148.03 | 167.16 | 183.23 | 212.70 | 174.02 | 143.86 | 191.94 | 192.69 | ||||||||||
| Interest & Other Items | 7.86 | 4.43 | 9.06 | 5.20 | 4.08 | 2.57 | 2.96 | 3.48 | 4.12 | 3.33 | ||||||||||
| PBT | 118.17 | 137.06 | 138.97 | 161.96 | 179.15 | 210.13 | 171.06 | 140.38 | 187.82 | 189.36 | ||||||||||
| Taxes & Other Items | 42.34 | 45.51 | 48.91 | 50.90 | 49.87 | 64.21 | 51.48 | 34.75 | 54.52 | 52.30 | ||||||||||
| Net Income | 75.83 | 91.55 | 90.06 | 111.06 | 129.28 | 145.92 | 119.58 | 105.63 | 133.30 | 137.06 | ||||||||||
| EPS | 1.39 | 2.79 | 8.07 | 9.95 | 11.58 | 13.06 | 10.70 | 9.45 | 11.92 | 12.26 | ||||||||||
| DPS | 0.20 | 0.08 | 0.50 | 0.60 | 0.60 | 0.90 | 1.00 | 1.00 | 5.10 | 5.10 | ||||||||||
| Payout ratio | 0.14 | 0.03 | 0.06 | 0.06 | 0.05 | 0.07 | 0.09 | 0.11 | 0.43 | 0.42 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Advanced Enzyme Technologies Ltd | 31.16 | 3.03 | 1.37% |
| Gujarat Fluorochemicals Ltd | 109.20 | 8.00 | 0.07% |
| Vinati Organics Ltd | 56.47 | 7.41 | 0.40% |
| Navin Fluorine International Ltd | 63.57 | 7.22 | 0.43% |
Price Comparison
Compare ADVENZYMES with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Advanced Enzyme Technologies Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HDFC Multi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4583% | Percentage of the fund’s portfolio invested in the stock 0.11% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 189/221 (-12) |
Motilal Oswal Nifty Microcap 250 Index Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1034% | Percentage of the fund’s portfolio invested in the stock 0.24% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 98/309 (-7) |
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.14% | Change in the portfolio weight of the stock over the last 3 months 0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 67/102 (-8) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
ADVENZYMES has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 1.37%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹13.73 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 18, 2024
Dividend/Share
₹1.10
Ex DateEx Date
Jul 18, 2024
Cash Dividend
Ex DateEx DateMay 17, 2024
Dividend/Share
₹4.00
Ex DateEx Date
May 17, 2024
Cash Dividend
Ex DateEx DateAug 4, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateMay 19, 2023
Dividend/Share
₹4.00
Ex DateEx Date
May 19, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Aug 11, 2022
The Board of Directors of Advanced Enzymes USA (AEU), a wholly owned subsidiary of Advanced Enzyme Technologies has accorded its approval for formation of a new corporation in California (US) to be named as Starya Labs, Inc (Starya Labs). In view of this, Starya Labs will be a step down wholly owned subsidiary of Advanced Enzyme Technologies. Cal-India Foods International USA (SEB), a step-down wholly owned subsidiary of Advanced Enzyme Technologies and wholly owned subsidiairy of AEU to spin-off and transfer its enzyme/probiotic laboratory testing services (SEB Lab) together with certain assets and liabilities related to the said SEB Lab into Starya Labs. The said new corporation, Starya Labs will be a wholly owned subsidiary of AEU. Powered by Capital Market - Live
The revenue de-grew by 3% in Americas, 27% in Europe, 9% in Asia (ex-India) while it grew by 8% in rest of the world. On the segmental front, the revenue from human nutrition segment declined by 2% YoY to Rs 99.2 crore while animal nutrition income grew by 6% YoY to Rs 18.1 crore in second quarter of FY25. The bio-processing segment revenue slipped 33% to Rs 16.8 crore while specialized manufacturing segment rose 9% to Rs 12 crore in September 2024 quarter over September 2023 quarter. The domestic sales constituted about 48% of revenue from operations during Q2 FY25 as compared to 52% during Q2 FY24. International sales were 52% of revenue from operations during Q2 FY25 as compared to 48% during same quarter last year. EBITDA de-grew by 17% YoY to Rs 42.4 crore in the second quarter. EBITDA margin was 29% and PAT margin stood at 23% during the quarter. Profit before tax was at Rs 42.21 crore during Q2 of FY25, down 11.93% YoY. On outlook front, the company stated, 'Advanced Enzymes is constantly working towards improving and strengthening its business model, and will continue to focus on all three divisions - Human Nutrition, Animal Nutrition and Bio-Processing including developing, adding and launching more products in the target market of probiotics. The company is confident that its existing capacities and capital investments would serve well to expand its enzymes and probiotics business.' Advanced Enzyme Technologies is a research driven company with global leadership in the manufacturing of enzymes and probiotics. The company provides eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. Its aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions. Powered by Capital Market - Live
Net profit of Advanced Enzyme Technologies declined 4.59% to Rs 32.83 crore in the quarter ended September 2024 as against Rs 34.41 crore during the previous quarter ended September 2023. Sales declined 7.44% to Rs 146.10 crore in the quarter ended September 2024 as against Rs 157.84 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales146.10157.84 -7 OPM %29.0332.51 - PBDT51.1056.65 -10 PBT42.2147.93 -12 NP32.8334.41 -5 Powered by Capital Market - Live
Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Net profit of Advanced Enzyme Technologies rose 18.54% to Rs 34.15 crore in the quarter ended June 2024 as against Rs 28.81 crore during the previous quarter ended June 2023. Sales rose 4.92% to Rs 154.52 crore in the quarter ended June 2024 as against Rs 147.28 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales154.52147.28 5 OPM %33.1229.89 - PBDT57.2950.04 14 PBT48.6741.41 18 NP34.1528.81 19 Powered by Capital Market - Live
Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
Stock alert: Indus Towers, Gland Pharma, Advanced Enzyme, DMart, Sapphire Foods
Motilal Oswal Buys Shares Of Advanced Enzyme Technologies For Rs 425.5 Crore
Advanced Enzyme jumps 4% as ICICI Mutual Fund acquires stake
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.24%, vs industry avg of 6.15%
Increasing Market Share
Over the last 5 years, market share increased from 0.77% to 0.78%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 3.72%, vs industry avg of -1.28%